CNS Pharmaceuticals, Inc. (CNSP)

0.2040 +0.0105 (+5.43%) 收市：04:00PM EDT

CNS Pharmaceuticals, Inc.

2100 West Loop South
Suite 900
Houston, TX 77027
United States
800 946 9185
https://www.cnspharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 3

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. John Michael Climaco Esq., J.D.	CEO, President & Director	525k	無	1969
Mr. Christopher S. Downs CPA, CTP, FP&A	Chief Financial Officer	382.16k	無	1979
Dr. Sandra L. Silberman M.D., Ph.D.	Chief Medical Officer	261.2k	無	1955
Dr. Waldemar Priebe Ph.D.	Founder	無	無	無
Dr. Donald H. Picker Ph.D.	Chief Science Officer	無	無	1946

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

公司管治

截至 無 止，CNS Pharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。